Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
38 hedge funds and large institutions have $13.5M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
9% more funds holding
Funds holding: 35 → 38 (+3)
1% less capital invested
Capital invested by funds: $13.6M → $13.5M (-$107K)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
63% less call options, than puts
Call options by funds: $132K | Put options by funds: $356K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JIR
James Investment Research
Alpha,
Ohio
|
+$408K |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
+$331K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$189K |
| 4 |
PP
PDT Partners
New York
|
+$91.7K |
| 5 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$88.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$196K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$112K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$110K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$97K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$57.1K |
JNP Hedge Fund Activity: Q2 2014 in Review
38 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q2 2014, worth a combined $13.5M — down 0.79% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new JNP positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was James Investment Research, adding an estimated $408K. The largest seller was Renaissance Technologies, cutting an estimated $196K.
- 38 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q2 2014, up from 35 in Q1 2014.
- Funds reported $13.5M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q2 2014, down 0.79% quarter-over-quarter.
- 7 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q2 2014 and 4 closed out, a net change of +3 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q2 2014 was James Investment Research, an estimated $408K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q2 2014 was Renaissance Technologies, an estimated $196K sold.
Based on aggregated 13F filings for Q2 2014.